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Abstract
Skin protects the body from the environment and is an important component of the innate and adaptive immune systems.
Atopic dermatitis and contact dermatitis are among the most frequent inflammatory skin diseases and are both determined
by multigenic predisposition, environmental factors, and aberrant immune response. Peptidoglycan Recognition Proteins
(Pglyrps) are expressed in the skin and we report here that they modulate sensitivity to experimentally-induced atopic
dermatitis and contact dermatitis. Pglyrp3
2/2 and Pglyrp4
2/2 mice (but not Pglyrp2
2/2 mice) develop more severe
oxazolone-induced atopic dermatitis than wild type (WT) mice. The common mechanism underlying this increased
sensitivity of Pglyrp3
2/2 and Pglyrp4
2/2 mice to atopic dermatitis is reduced recruitment of Treg cells to the skin and
enhanced production and activation Th17 cells in Pglyrp3
2/2 and Pglyrp4
2/2 mice, which results in more severe
inflammation and keratinocyte proliferation. This mechanism is supported by decreased inflammation in Pglyrp3
2/2 mice
following in vivo induction of Treg cells by vitamin D or after neutralization of IL-17. By contrast, Pglyrp1
2/2 mice develop
less severe oxazolone-induced atopic dermatitis and also oxazolone-induced contact dermatitis than WT mice. Thus,
Pglyrp3 and Pglyrp4 limit over-activation of Th17 cells by promoting accumulation of Treg cells at the site of chronic
inflammation, which protects the skin from exaggerated inflammatory response to cell activators and allergens, whereas
Pglyrp1 has an opposite pro-inflammatory effect in the skin.
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Introduction
Skin protects the body from the environment and is the largest
organ in mammals. Besides forming a mechanical barrier, skin is
an important component of the innate and adaptive immune
systems rich in anti-microbial peptides and antigen-sensing cells,
and it maintains the proper homeostatic balance between pro- and
anti-inflammatory responses. Atopic dermatitis and contact
dermatitis are among the most frequent inflammatory skin
diseases, both determined by multigenic predisposition, environ-
mental factors, and aberrant immune response. Atopic dermatitis
has a prevalence of 15–30% in children and 2–10% in adults,
involves loss of barrier function of the skin and type I hyper-
sensitivity to environmental allergens, and is manifested by pruritic
erythematosus skin eruptions and increased IgE response, often
with aggravating bacterial infections [1–3]. Allergic contact
dermatitis (contact hypersensitivity) has a prevalence of 2–20%
and involves type IV (delayed-type) hypersensitivity to environ-
mental allergens, manifested by erythematosus skin infiltrations
with inflammatory cells [2,4,5].
Peptidoglycan Recognition Proteins (PGRPs or Pglyrps) are a
family of innate immunity proteins expressed in the skin. PGRPs
are conserved from insects to mammals, recognize bacterial
peptidoglycan, and function in antibacterial immunity. Mammals
have four PGRPs, Pglyrp1, Pglyrp2, Pglyrp3, and Pglyrp4, which
were initially named PGRP-S, PGRP-L, PGRP-Ia, and PGRP-Ib,
respectively [6,7]. Three PGRPs, Pglyrp1, Pglyrp3, and Pglyrp4
are directly bactericidal [8–11], whereas Pglyrp2 is an N-
acetylmuramoyl-L-alanine amidase that hydrolyzes peptidoglycan
[12,13]. Pglyrp1 is highly expressed in PMN’s granules and to a
much lower extent in other cells [7,14,15]. Pglyrp2 is constitutively
expressed in the liver and secreted into blood, and its expression is
induced in keratinocytes and other epithelial cells [12,13,16–20].
Pglyrp3 and Pglyrp4 have the highest expression in the skin
and are also expressed in the salivary glands, throat, tongue,
esophagus, stomach, intestine, and eyes [8,21,22]. Similar to
Pglyrp1 and Pglyrp2, Pglyrp3 and Pglyrp4 are secreted and their
expression in these tissues is both constitutive and inducible.
We hypothesized that PGRPs play a role in the development
atopic dermatitis and contact dermatitis because of (a) the
prominent expression of PGRPs in the skin, (b) the location of
Pglyrp3 and Pglyrp4 genes in the epidermal differentiation gene
cluster in the psoriasis sensitivity psors4 locus, (c) coordinated
expression of Pglyrp3 and Pglyrp4 with other genes in the psors4
locus, (d) previous evidence of genetic association of Pglyrp3 and
Pglyrp4 variants with psoriasis, which is another genetically- and
environmentally-determined skin disease [23,24], and (e) the
ability of mammalian PGRPs to protect mice against experimental
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arthritis [25]. Here we tested this hypothesis using PGRP-deficient
mice and mouse models of chemically-induced atopic dermatitis
and contact dermatitis.
Our results show that Pglyrp3
2/2 and Pglyrp4
2/2 mice (but not
Pglyrp2
2/2 mice) are more sensitive to the development of
experimental atopic dermatitis than wild type (WT) mice. The
common mechanism underlying this increased sensitivity of
Pglyrp3
2/2 and Pglyrp4
2/2 mice is reduced recruitment of Treg
cells to the skin and enhanced production and activation Th17
cells in Pglyrp3
2/2 and Pglyrp4
2/2 mice, which results in more
severe inflammation and keratinocyte proliferation. By contrast,
Pglyrp1
2/2 mice are less sensitive than WT mice to both
experimental atopic dermatitis and contact dermatitis. Thus,
Pglyrp3 and Pglyrp4 limit over-activation of Th17 cells by
promoting accumulation of Treg cells at the site of chronic
inflammation, which protects the skin from exaggerated inflam-
matory response to cell activators and allergens. By contrast,
Pglyrp1 has an opposite pro-inflammatory effect in the skin.
Results
Pglyrp3
2/2 and Pglyrp4
2/2 mice have enhanced
inflammatory response in the oxazolone model of atopic
dermatitis
Repeated epicutaneous sensitization with oxazolone is an
established mouse model of atopic dermatitis [3,26]. Initial
sensitization of mice with oxazolone through abdominal skin,
followed by6-dayrest and application ofoxazolonetotheearsevery
other day for 20 days induced in WT BALB/c mice progressive
moderate inflammation manifested by some redness and swelling
(Figure 1A). Similar application of oxazolone to Pglyrp3
2/2 or
Pglyrp4
2/2 mice induced significantly enhanced inflammation,
manifested first by increased redness and significantly increased
swelling, accompanied by scaling (Figure 1A). This enhanced
response was unique for Pglyrp3
2/2 and Pglyrp4
2/2 mice, because it
was not observed in Pglyrp1
2/2, Pglyrp2
2/2,a n dPglyrp1
2/2
Pglyrp2
2/2 mice, and was dominant, because it was still observed
in Pglyrp1
2/2Pglyrp3
2/2 and Pglyrp2
2/2Pglyrp3
2/2 double-knock-
out mice and in Pglyrp1
2/2Pglyrp2
2/2Pglyrp3
2/2 and Pglyrp1
2/2
Pglyrp2
2/2Pglyrp4
2/2 triple-knockout mice (Figure 1A). Deletion of
Pglyrp1 had the opposite effect – Pglyrp1
2/2 single knockout mice
showed reduced ear swelling on days 16 through 20 of oxazolone
application (Figure 1A). Theseresults indicate that inWT mice both
Pglyrp3 and Pglyrp4 have a protective effect against severe atopic
dermatitis-like inflammation, whereas Pglyrp1 has an enhancing
proinflammatory effect and Pglyrp2 has little effect on the response
to oxazolone.
To determine the pathologic basis of higher sensitivity of
Pglyrp3
2/2 and Pglyrp4
2/2 mice to oxazolone, we compared the
histology of oxazolone-induced skin lesions in WT and Pglyrp-
deficient mice. Ears in untreated WT mice have one- to two-cell
thick epidermis and few-cell thick subepidermal layer with blood
vessels, sebaceous glands, hair follicles, muscle bundles, and
central fat and connective tissue layer, with total thickness of
approximately 200 mm. Histology of all untreated Pglyrp-deficient
mice was similar to WT mice (Figure 2). Sensitization and 10
oxazolone applications to the ears (every other day) induced strong
inflammatory response that was very severe in Pglyrp3
2/2 mice
and Pglyrp4
2/2 mice. Cross-sections of the oxazolone-treated ears
revealed severe acanthosis (thickening of the epidermis due to
proliferation of keratinocytes), parakeratosis (retention of kerati-
nocytes’ nuclei in stratum corneum), and marked thickening of the
sub-epidermal layer with spongiosis (intercellular edema) and
dense cellular infiltrates (composed primarily of mononuclear cells
and some polymorphonuclear cells) that were all highly prominent
in Pglyrp3
2/2 mice and Pglyrp4
2/2 mice (Figure 2A) and in all
other double and triple knockout mice deficient in Pglyrp3 (not
shown). All these changes are highly characteristic of atopic
dermatitis lesions. These mice did not develop rete pegs
(downward papillary projections of epidermis), which are charac-
teristic of psoriasis, but not atopic dermatitis. WT mice (Figure 2A),
Pglyrp1
2/2 mice, Pglyrp2
2/2 mice, and Pglyrp1
2/2Pglyrp2
2/2 mice
(not shown) all showed much less severe acanthosis, parakeratosis,
edema, and cell infiltrations, and less thickening of the
subepidermal layer.
Inflammatory response to oxazolone was accompanied by a
marked increase in the concentration of serum IgE, consistent with
oxazolone inflammation being a model of atopic dermatitis (which
is type I hypersensitivity associated with increased IgE production).
The serum IgE levels in Pglyrp3
2/2 mice and Pglyrp4
2/2 mice, as
well as Pglyrp1
2/2Pglyrp3
2/2 and Pglyrp2
2/2Pglyrp3
2/2 double-
knockout mice and in Pglyrp1
2/2Pglyrp2
2/2Pglyrp3
2/2 and
Pglyrp1
2/2Pglyrp2
2/2Pglyrp4
2/2 triple-knockout mice were all
significantly higher than in WT and in Pglyrp1
2/2, Pglyrp2
2/2,
and Pglyrp1
2/2Pglyrp2
2/2 mice (Figure 3). Pglyrp2 also played a
minor role, because Pglyrp2
2/2Pglyrp3
2/2 double-knockout mice
and Pglyrp1
2/2Pglyrp2
2/2Pglyrp3
2/2 and Pglyrp1
2/2Pglyrp2
2/2
Pglyrp4
2/2 triple-knockout mice had higher serum IgE levels than
Pglyrp3
2/2 and Pglyrp4
2/2 single-knockout mice.
These results demonstrate that deletion of Pglyrp3 or Pglyrp4
highly predisposes mice to atopic dermatitis-like lesions in response
to oxazolone, and thus in WT mice Pglyrp3 or Pglyrp4 protect the
skin from excessive inflammation in the oxazolone model of atopic
dermatitis.
Pglyrp-deficient mice have reduced response in the
oxazolone model of contact dermatitis
Single epicutaneous sensitization with oxazolone followed by a
single epicutaneous challenge in a different area is an established
mouse model of allergic contact dermatitis (contact hypersensitiv-
ity) due to type IV hypersensitivity [27,28]. Sensitization of mice
with oxazolone through abdominal skin, followed by 6-day rest
and a single application of oxazolone to the ears induced on the
next day a strong inflammatory response in WT BALB/c mice,
manifested by redness and swelling (Figure 1B). Similar application
of oxazolone to Pglyrp-deficient mice induced significantly lower
inflammation, manifested by significantly reduced ear swelling
compared to WT mice, especially in Pglyrp1
2/2 mice, and to some
extent in Pglyrp2
2/2 and Pglyrp4
2/2 mice. The reduced
responsiveness was dominant, because it was still observed in
Pglyrp1
2/2Pglyrp2
2/2 (most affected), Pglyrp1
2/2Pglyrp3
2/2, and
Pglyrp2
2/2Pglyrp3
2/2 double-knockout mice and in Pglyrp1
2/2
Pglyrp2
2/2Pglyrp3
2/2 triple-knockout mice (Figure 1B).
To determine the pathologic basis of this lower response to
oxazolone in the contact dermatitis model in Pglyrp-deficient
mice, we compared the ear histology in oxazolone-treated WT
and Pglyrp-deficient mice. Sensitization and single oxazolone
application to the ears induced strong inflammatory response in
WT mice manifested by marked spongiosis of the sub-
epidermal layer with cellular infiltrates of epidermal and sub-
epidermal layers with mononuclear and polymorphonuclear
cells (but no acanthosis, parakeratosis, rete pegs, or scaling,
which histologically differentiates contact dermatitis from
atopic dermatitis and psoriasis) (Figure 2B). Pglyrp1
2/2 and
Pglyrp1
2/2Pglyrp2
2/2 mice still had cellular infiltrates, but had
substantially reduced swelling,c o m p a r e dt oW Tm i c e ,m o s t l y
due to reduced edema (Figure 2B). These results indicate that in
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Pglyrp4) has an enhancing proinflammatory role in this model
of contact dermatitis.
Thus, altogether our results indicate that individual PGRPs
have selective and distinct effects on skin inflammation. In WT
mice Pglyrp3 and Pglyrp4 offer protection in the oxazolone atopic
dermatitis model, Pglyrp1 has a pro-inflammatory effect both
atopic and contact dermatitis models, and Pglyrp2 has little effect
on the atopic dermatitis and has a pro-inflammatory effect in the
contact dermatitis model of skin inflammation.
Expression of PGRPs in inflamed ears
To gain further insight how individual PGRPs influence
sensitivity to both models of skin inflammation, we compared
expression of all PGRPs in the ears in untreated and oxazolone-
treated mice. In both atopic and contact dermatitis models
Figure 1. Pglyrp3
2/2 and Pglyrp4
2/2 mice have enhanced response in the oxazolone model of atopic dermatitis and Pglyrp1
2/2 and
other Pglyrp
2/2 mice have reduced response in the oxazolone model of contact dermatitis. (A) Atopic dermatitis model: sensitization
followed by 10 applications of oxazolone to the ears every other day induces mild inflammation (left) and mild ear swelling (right) in WT mice (black
triangles) and severe inflammation with increased redness, scaling, and extensive ear swelling in Pglyrp3
2/2 and Pglyrp4
2/2 mice (color triangles). (B)
Contact dermatitis model: sensitization followed by a single application of oxazolone to the ears induces strong ear swelling in WT mice (black
triangles) and reduced ear swelling in Pglyrp1
2/2, Pglyrp2
2/2, and Pglyrp4
2/2 mice (color triangles). Means 6 SEM (SEM were often smaller than the
symbols in this and other figures); N=9–17 mice/group; significance of differences between Pglyrp
2/2 and WT mice: *, P,0.02; **, P,0.0001.
doi:10.1371/journal.pone.0024961.g001
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PLoS ONE | www.plosone.org 3 September 2011 | Volume 6 | Issue 9 | e24961Figure 2. Ear histology in WT and Pglyrp-deficient mice in atopic dermatitis and contact dermatitis models of skin inflammation. (A)
Oxazolone model of atopic dermatitis: sensitization and 10 applications of oxazolone to the ears every other day induced acanthosis (Ac),
parakeratosis (Pk), marked thickening of the sub-epidermal layer with spongiosis (Sp) and dense cellular infiltrates of primarily mononuclear and
some polymorphonuclear cells (high magnification insets), that were all highly prominent in Pglyrp3
2/2 mice and Pglyrp4
2/2 mice and much less
severe in WT mice. (B) Oxazolone model of contact dermatitis: sensitization and a single application of oxazolone to the ears induced strong
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expression in the ears in all strains of mice (except Pglyrp1
2/2
mice, in which Pglyrp1 gene is deleted) that was significantly higher
than in untreated mice (Figure 4). The expression of Pglyrp1 was
significantly higher in all Pglyrp-deficient mice
2 than in WT mice
early (day 13) in the atopic dermatitis model, which correlates with
their higher inflammatory response. This increase in Pglyrp1
mRNA in the ears is likely due to increased infiltration with
PMNs, because PMNs highly express Pglyrp1 and expression of
Pglyrp1 is not inducible in any of the cell types previously studied,
including lymphocytes, monocytes, macrophages, and keratino-
cytes [8,14,15]. The expression of Pglyrp2 was only modestly
increased early in the atopic dermatitis model and returned to the
untreated level later in this model, and was not significantly
changed at any time point in the contact dermatitis model,
consistent with the little effect of Pglyrp2 in both atopic and
contact dermatitis models (Figure 1). Pglyrp1 and Pglyrp2 were
also constitutively expressed in the cervical lymph nodes at a
similar level as in the ears, but following oxazolone treatment their
expression in the cervical lymph nodes did not significantly change
(data not shown), despite extensive stimulation and expansion of
immune cells in the draining lymph nodes, which increased in
diameter from ,0.5 mm in untreated mice to .3 mm after 20
days of oxazolone treatment.
Pglyrp3 has high constitutive expression in untreated skin
[8,21]. Pglyrp3 mRNA expression initially increased and later
decreased in the atopic dermatitis model, and decreased in the
contact dermatitis model. Pglyrp4 has lower constitutive expres-
sion in untreated skin than Pglyrp3. Expression of Pglyrp4 mRNA
was highly increased in the atopic dermatitis model and was the
highest in Pglyrp2
2/2Pglyrp3
2/2 and Pglyrp3
2/2 mice, suggesting a
possibility of compensatory expression of Pglyrp4 in mice deficient
in Pglyrp3 or changes in the regulation of transcription or stability
of Pglyrp4 mRNA, since Pglyrp3 and Pglyrp4 genes are tightly
linked in the psoriasis sensitivity locus on chromosome 3 in mice
and their expression is correlated with the expression of
keratinocytes differentiation genes [21]. To further investigate
which cells express Pglyrp3 and Pglyrp4 in the untreated and
oxazolone-treated skin, we analyzed the expression of Pglyrp3 and
Pglyrp4 proteins by immunohistochemistry. Pglyrp3 and Pglyrp4
were expressed in epidermal keratinocytes in untreated ears, and
in oxazolone-treated ears they were primarily expressed in the
upper layers of differentiated keratinocytes (Figure 5). Pglyrp3 and
Pglyrp4 expression was not induced in other cell types, such as
infiltrating inflammatory cells in oxazolone-treated ears. More-
over, Pglyrp3 and Pglyrp4 were not expressed in the cervical
lymph nodes in untreated mice and their expression there was not
induced following oxazolone treatment (data not shown). These
results indicate that Pglyrp3 and Pglyrp4 are primarily expressed
in keratinocytes, but not in immune or inflammatory cells, and
thus these results raise the possibility that Pglyrp3 and Pglyrp4
exert their protective effects in the oxazolone-induced atopic
dermatitis by modulating the function of keratinocytes, which are
known to produce many pro-inflammatory cytokines and
chemokines.
Pglyrp3
2/2 and Pglyrp4
2/2 mice have increased Th17
cells and Th17 responses in the skin
To determine the cellular basis for the differences in the
inflammatory responses in Pglyrp-deficient mice, we next deter-
mined the types of inflammatory cells in the ears in both models of
skin inflammation, and then we determined which cell types
significantly differed in Pglyrp-deficient mice compared to WT
mice. This was first accomplished by measuring the amounts of
mRNA for several marker genes characteristic of various immune
and inflammatory cell types in the untreated and the affected ears.
To determine which marker genes (and thus cell types) are
increased or decreased in Pglyrp-deficient mice compared to WT
mice, we calculated how many times higher or lower they were
induced in Pglyrp-deficient mice than in WT mice (fold induction
in Pglyrp-deficient mice/fold induction in WT mice).
Prolonged treatment with oxazolone in the atopic dermatitis
model induced increases in mRNA of several cell types in WT
mice, and especially mature B cells, CD8
+ T cells, monocytes,
PMNs, and mast cells, as well as changes associated with de-
differentiation, proliferation, and activation of keratinocytes,
which are all expected changes consistent with the atopic
dermatitis model (Figure 6A and Figure S1). Atopic dermatitis-
sensitive mice (Pglyrp3
2/2, Pglyrp4
2/2, and Pglyrp2
2/2Pglyrp3
2/2
mice) had increased expression of genes characteristic of B cells
and T cells. Also increased was Rorct mRNA, which is
preferentially expressed in Th17 cells [29] (Figure 6A and Figure
S1).
Short-term treatment with oxazolone in the contact dermatitis
model in WT mice induced increases primarily in monocytes and
PMNs at 6 hrs after challenge (Figure 6B and Figure S2) and later
in T cells (18 hrs, not shown). Contact dermatitis-resistant mice
(Pglyrp1
2/2, Pglyrp2
2/2, and Pglyrp1
2/2Pglyrp2
2/2 mice) had
initially (6 hrs after challenge) increased B cells and Treg cells and
decreased other cell-types, compared to WT mice (Figure 6B and
Figure S2). Later (18 hrs after challenge) the cell markers in
Figure 3. Pglyrp3
2/2 and Pglyrp4
2/2 mice have higher serum IgE
levels than WT mice in the oxazolone model of atopic
dermatitis. Sensitization followed by 10 applications of oxazolone to
the ears every other day induced higher level of serum IgE in Pglyrp3
2/2
and Pglyrp4
2/2 mice than in WT, Pglyrp1
2/2 or Pglyrp2
2/2 mice; means
6 SEM of 8–20 mice/group; *, P,0.002; **, P,0.0001, Pglyrp
2/2 versus
WT.
doi:10.1371/journal.pone.0024961.g003
inflammatory response in WT mice with marked spongiosis of the sub-epidermal layer (Sp) and cellular infiltrates of epidermal and sub-epidermal
layers, composed of mononuclear and polymorphonuclear cells; Pglyrp1
2/2 and Pglyrp1
2/2Pglyrp2
2/2 mice still had cellular infiltrates, but had
substantially reduced swelling, compared to WT mice, mostly due to reduced edema. H&E stained cross-sections; bar=200 mm for all panels, except
high magnification insets (the magnified areas are shown by rectangles).
doi:10.1371/journal.pone.0024961.g002
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2/2 and Pglyrp1
2/2Pglyrp2
2/2 mice were similar (most
cells) or increased (monocytes), compared to WT mice (not
shown), consistent with comparable cell infiltrates seen in all mice
on tissue sections on day 1 (Figure 2B).
To further define the cell types responsible for differential
sensitivity of Pglyrp-deficient mice to atopic dermatitis and contact
dermatitis, we measured the expression of an extended panel of
cytokines, chemokines, and other marker genes characteristic of
Th1, Th2, Th17, Treg, NK, and other cell types to determine
which of these genes were differentially induced in the affected skin
in Pglyrp-deficient mice, compared to WT mice. We included these
cell types, because in addition to Th1 and Th2 cells, Th17 cells
and other cell types may also be involved in these skin diseases.
Prolonged epicutaneous sensitization with oxazolone (20 days),
which induced atopic dermatitis-like skin inflammation, was
accompanied in WT mice by high activation (more than 15-fold)
of 14 out of 44 studied genes in the affected skin. These genes were
Ifng (Th1), Il4 and Il10 (Th2), Cxcl2, Cxcl5, and Il21 (Th17),
Cxcl9 and Cxcl10 (NK cells), and Ccl3, Ccl4, Ccr5, Fasl, Il1b, and
Il6 (several cell types) (Figure 7A and Figures S3 and S4). Atopic
dermatitis-sensitive mice initially (day 13) had several genes
activated higher than in WT mice, characteristic of several cell
types, including Th2 and Th17 (Figure 7A and Figure S3). Later
(day 20), atopic dermatitis-sensitive mice (Pglyrp3
2/2, Pglyrp4
2/2,
and Pglyrp2
2/2Pglyrp3
2/2 mice) had four genes characteristic of
Th17 cells (Cxcl1, Cxcl5, IL17a, IL22) and one gene characteristic
of several cell types (Ccl2) activated more than three-fold higher in
Pglyrp-deficient than in WT mice (Figure 7A and Figure S4).
A single oxazolone challenge in sensitized WT mice (in the
contact dermatitis model) also induced many genes characteristic of
several cell types, and the early (6 hrs) activation of these genes in
Pglyrp-deficient mice was mostly reduced, compared to WT mice
(Figure 7B and Figure S5). These results are consistent with lower
clinical responses of Pglyrp-deficient mice to a single oxazolone
challenge in the contact dermatitis model (Figures 1B and 2B).
The above results indicate that the atopic dermatitis-sensitive
Pglyrp-deficient mice have increased activity of Th17 cells in the
affected skin, compared to WT mice. To further investigate the
role Th17 cells (and other Th cell types) in increased sensitivity of
Pglyrp-deficient mice in atopic dermatitis model, we used flow
cytometry to directly measure Th cell types in the ears, draining
lymph nodes, and the spleen.
Untreated ears in WT and Pglyrp
2/2 mice had ,400 CD4
+
cells/ear, whereas after sensitization and 20 days of oxazolone
treatment the numbers of CD4
+ cells/ear increased .50 times to
,18,000–19,000/ear in WT and Pglyrp3
2/2 mice (Figure 8A).
Regarding Th cell subpopulations, oxazolone treatment for 13
days induced significantly higher numbers of Th2 cells (CD4
+IL-
4
+) in the affected ears in Pglyrp3
2/2 mice compared to WT mice,
whereas oxazolone treatment for 20 days induced significantly
Figure 4. Pglyrp1, Pglyrp2, Pglyrp3, and Pglyrp4 expression is increased in the affected skin in the atopic dermatitis and contact
dermatitis models of inflammation. The amounts of each PGRP mRNA in WT mice and in the indicated Pglyrp-deficient mice sensitized and
treated with oxazolone every other day (atopic dermatitis model) or sensitized and treated with oxazolone at 0 hrs only (contact dermatitis model)
were measured by qRT-PCR. The results are means of 3–4 mice 6 SEM; *, P,0.04; **, P,0.001, treated versus untreated; ¤,P ,0.04; ¤¤,P ,0.001,
Pglyrp
2/2 versus WT.
doi:10.1371/journal.pone.0024961.g004
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+IL-17
+) in the affected ears in
Pglyrp3
2/2 mice compared to WT mice (Figure 8A, B and C).
Thus, on day 20 in Pglyrp3
2/2 mice the numbers of Th17 cells in
the ears increased from undetectable (,10/ear) to ,650 Th17
cells/ear, 3.5 times higher than in WT mice (Figure 8A). Virtually
all detectable IL-17
+ cells in the oxazolone-treated ears were CD4
+
(Th17 cells) and there were very few (,50/ear, not shown) other
IL-17
+ cells in the inflamed skin (such as CD8
+, c/d T cells, or
NKT cells), and therefore the observed increases in the numbers
IL-17
+ cells mostly represent increases in Th17 cells (CD4
+IL-17
+).
There was no significant difference in the numbers of Th1
(CD4
+IFN-c
+) and Th2 (CD4
+IL-4
+) cells in the ears of WT and
Pglyrp3
2/2 mice on day 20 (Figure 8C). Oxazolone-treated mice
had substantially swollen cervical lymph nodes (.3m m i n
diameter, compared to ,0.5 mm in untreated mice), where on
day 13 the numbers of Th2 cells and on day 20 the numbers of all
Figure 5. Pglyrp3 and Pglyrp4 are expressed primarily in the differentiated epidermal cells in both untreated and oxazolone-
treated skin in the atopic dermatitis model. Transverse sections of the ears from either untreated or oxazolone-treated mice (sensitization
followed by 10 applications of oxazolone to the ears every other day) were stained by an immunoperoxidase method with either anti-Pglyrp3 or anti-
Pglyrp4 antibodies or IgG (negative control); bar=50 mm.
doi:10.1371/journal.pone.0024961.g005
Pglyrp3/4 Promote Treg and Inhibit Th17 Responses
PLoS ONE | www.plosone.org 7 September 2011 | Volume 6 | Issue 9 | e24961Th cell types were significantly higher in Pglyrp3
2/2 mice
compared to WT mice (Figure 8B and C).
These results indicate initial (day 13) preferential activation of
Th2 cells in the affected ears and draining lymph nodes in
Pglyrp3
2/2 mice compared to WT mice, consistent with B-cell-
dependence of atopic dermatitis model. However, continued
treatment with oxazolone (20 days) showed a switch to preferential
infiltration of the affected ears with Th17 cells in Pglyrp3
2/2 mice
compared to WT mice (Figure 8), consistent with our mRNA gene
expression data (Figures 6 and 7 and Figures S1, S3, and S4).
IL-17 is required for enhanced response to oxazolone in
Pglyrp3
2/2 mice
To further study the role of IL-17 (Th17 cytokine) in high
sensitivity of Pglyrp3
2/2 mice to oxazolone-induced atopic
dermatitis, we determined the protein levels of an IL-17-induced
chemokine, CXCL-1, in the ears of WT and Pglyrp3
2/2 mice.
CXCL-1 was undetectable (,7 pg/ear) in the ears of untreated
mice, and after sensitization and 20 days of skin treatment with
oxazolone, the amount of CXCL-1 increased to .350 pg/ear in
Pglyrp3
2/2 mice, the level that was significantly higher than in WT
mice (Figure 9A).
To determine whether IL-17 is required for the high sensitivity
of Pglyrp3
2/2 mice to atopic dermatitis, we compared the severity
of ear inflammation in oxazolone-treated Pglyrp3
2/2 mice in
which IL-17 activity was inhibited with neutralizing anti-IL-17
mAb. In vivo neutralization of IL-17 activity in Pglyrp3
2/2 mice in
the oxazolone-induced atopic dermatitis significantly reduced ear
inflammation, compared to mice treated with an isotype control
IgG (Figure 9B). These results demonstrate that IL-17 is required
Figure 6. Pglyrp3
2/2 and Pglyrp4
2/2 mice have increased Th17 cells in the affected skin in the atopic dermatitis model, whereas
Pglyrp1
2/2 and Pglyrp2
2/2 mice have most cell types decreased (except B cells and Treg cells) in the contact dermatitis model.
Expression of a panel of marker genes characteristic of various inflammatory cell types in the ears of mice after (A) sensitization and 10 applications of
oxazolone to the ears every other day, or (B) after sensitization and 6 hrs after a single application of oxazolone to the ears, measured by qRT-PCR is
shown. For WT mice (left panels in A and B), the ratio of the amount of mRNA in oxazolone-treated to untreated mice for each gene (fold induction by
oxazolone) is shown; for Pglyrp
2/2 mice (right panels in A and B), the results are the ratios of fold induction of each gene by oxazolone in Pglyrp
2/2
mice to fold induction of each gene by oxazolone in WT mice (which represents the fold difference in the response to oxazolone in Pglyrp
2/2 versus
WT mice). The results are means of 3 arrays from 4–5 mice/group in heat map format. The means 6 SEM bar graphs for these results are shown in
Figures S1 and S2.
doi:10.1371/journal.pone.0024961.g006
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2/2
mice in the atopic dermatitis model.
Pglyrp3
2/2 and Pglyrp4
2/2 mice have decreased
numbers of Treg cells in the skin
Because WT mice were able to limit skin inflammation in the
atopic dermatitis model more effectively than Pglyrp3
2/2 and
Pglyrp4
2/2 mice, we then tested whether this difference is due to
impaired generation or function of regulatory T cells
(CD4
+FoxP3
+ Treg) in Pglyrp-deficient mice.
In the atopic dermatitis model WT mice efficiently recruited
Treg cells into the affected skin, as evidenced by an increase in
FoxP3-expressing Treg cells in the affected skin shown both by the
qRT-PCR (Figure 6A and Figure S1) and by flow cytometry, in
which high numbers of CD4
+FoxP3
+ Treg cells were found in the
affected skin in WT mice (Figure 8B–D). By contrast, atopic
dermatitis-sensitive Pglyrp-deficient mice (Pglyrp3
2/2, Pglyrp4
2/2
and Pglyrp2
2/2Pglyrp3
2/2 mice) all had lower expression of FoxP3
mRNA in the affected ears compared to WT mice (Figure 6A and
Figure S1). Pglyrp3
2/2 mice in the atopic dermatitis model also
Figure 7. Th17 gene expression profile is preferentially induced in the atopic dermatitis model in Pglyrp3
2/2 and Pglyrp4
2/2 mice,
whereas expression of most immune genes is reduced in the contact dermatitis model in Pglyrp
2/2 mice. Expression of a panel of
cytokines, chemokines, and other marker genes characteristic of Th1, Th2, Th17, Treg, NK, and other cell types in the ears of mice was measured by
qRT-PCR. (A) After sensitization and 10 applications of oxazolone to the ears every other day the expression of several Th17 marker genes was higher
in Pglyrp3
2/2 and Pglyrp4
2/2 mice than in WT mice. (B) After sensitization and a single application of oxazolone to the ears the expression of most of
immune marker genes was lower in Pglyrp
2/2 mice than in WT mice. For WT mice (left panels in A and B), the ratio of the amount of mRNA in
oxazolone-treated to untreated mice for each gene (fold induction by oxazolone) is shown; for Pglyrp
2/2 mice (right panels in A and B), the results are
the ratios of fold induction of each gene by oxazolone in Pglyrp
2/2 mice to fold induction of each gene by oxazolone in WT mice (which represents
the fold difference in the response to oxazolone in Pglyrp
2/2 versus WT mice). The results are means of 3 arrays from 4–5 mice/group in heat map
format. The means 6 SEM bar graphs for these results are shown in Figures S3, S4, and S5.
doi:10.1371/journal.pone.0024961.g007
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2/2 mice have high numbers Th17 and low numbers of Treg cells in the affected skin in the oxazolone model of
atopic dermatitis. (A) Numbers of CD4
+ cells and Th17 cells in the ears or (B–D) percentages of Th1, Th2, Th17, and Treg cells in the ears, cervical
lymph nodes, and spleen in sensitized WT and Pglyrp3
2/2 mice on days 13 or 20 of ear treatment with oxazolone, measured by flow cytometry;
means 6 SEM of 5–9 mice/group (*, P,0.05; **, P,0.005; Pglyrp3
2/2 versus WT) or representative dot plots are shown. (E) Expression of receptors for
chemokines that attract Treg cells in cervical lymph nodes of sensitized WT and Pglyrp3
2/2 mice on day 20 of ear treatment with oxazolone measured
by qRT-PCR; amounts of mRNA are shown as means 6 SEM of 3 arrays from 5 mice/group.
doi:10.1371/journal.pone.0024961.g008
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+FoxP3
+ Treg cells in the
affected skin compared to WT mice measured by flow cytometry
(Figure 8B–D). These results suggest impaired recruitment and/or
maintenance of Treg cells in the inflamed skin in Pglyrp3
2/2 and
Pglyrp4
2/2 mice.
To further investigate whether Pglyrp3
2/2 mice have less
efficient generation of induced Treg cells in lymphoid tissues in
general or less efficient recruitment and/or maintenance of these
cells in the inflamed skin, we compared the numbers of Treg cells
in the draining cervical lymph nodes and in the spleen of WT and
Pglyrp3
2/2 mice treated with oxazolone. Oxazolone-treated
Pglyrp3
2/2 mice on day 13 had lower numbers of Treg cells than
WT mice in cervical lymph nodes and spleen (Figure 8B).
However, at the peak of inflammation (day 20) Pglyrp3
2/2 mice
had similar numbers of Treg cells in the draining lymph nodes and
spleen compared to WT mice (Figure 8C). These results indicate
that Pglyrp3
2/2 mice can eventually generate sufficient numbers of
induced Treg cells in lymphoid organs and suggest a possible
reduced migration and retention of Treg cells in the affected skin.
There could be at least two reasons for this less efficient
recruitment of Treg cells to the skin in Pglyrp3
2/2 mice:
insufficient production of Treg-attracting chemokines in the skin,
and/or insufficient expression of receptors for these chemokines in
Treg cells in Pglyrp3
2/2 mice. Our results show lower expression
of mRNA for Treg-attracting chemokines, CCL-27 (both on days
13 and 20) and CCL-17 (on day 20), in the ears of oxazolone-
treated Pglyrp3
2/2 mice compared to WT mice (Figure 7A and
Figures S3 and S5), indicating insufficient production of Treg-
attracting chemokines in the skin in Pglyrp3
2/2 mice. To
investigate the second of the above-mentioned possibilities, we
determined whether Treg cells in the draining cervical lymph
nodes in Pglyrp3
2/2 mice had sufficient expression of receptors for
Treg-attracting chemokines (Ccr4, Ccr8, and Ccr10). The
expression of mRNA for Ccr4, Ccr8, and Ccr10 in the draining
cervical lymph nodes in oxazolone-treated Pglyrp3
2/2 mice and
WT mice was similar (Figure 8E). These results support the
conclusion that Treg cells in the draining lymph nodes in
oxazolone-treated Pglyrp3
2/2 mice have sufficient expression of
receptors for Treg-attracting chemokines, but that these Treg cells
are not recruited to the inflamed skin, likely because of the
insufficient production of Treg-attracting chemokines in the skin
(Figure 7A and Figures S3 and S4). Our results thus indicate that
Pglyrp3 promotes efficient population of the skin with Treg cells in
oxazolone-induced atopic dermatitis.
Induction of Treg cells in Pglyrp3
2/2 mice reduces Th17
cells and sensitivity to atopic dermatitis
To further investigate the role of Treg cells in high sensitivity of
Pglyrp3
2/2 mice to atopic dermatitis, we induced generation of
Treg cells by application of vitamin D to the skin (which is known
to induce Treg cells [30,31]) together with the sensitizing allergen,
oxazolone. Vitamin D applied to the ears of Pglyrp3
2/2 mice
together with oxazolone significantly reduced ear swelling
compared to Pglyrp3
2/2 mice similarly treated with oxazolone
alone (Figure 10A). Vitamin D applied to the ears (together with
oxazolone) also significantly increased the percentages of Treg cells
both in the ears and cervical lymph nodes (as expected [30,31]),
and, moreover, it significantly reduced the percentages of Th17
cells in the ears compared to the ears treated with oxazolone alone,
measured on day 20 by flow cytometry (Figure 10B–D). Thus,
increasing the numbers of Treg cells in the affected skin in
Pglyrp3
2/2 mice to the numbers found in WT mice could revert
the inflammatory phenotype of Pglyrp3
2/2 mice to the less
inflammatory phenotype characteristic of WT mice. These results
further demonstrate the critical role of Treg cells in preventing
high levels of Th17 cells in the skin and excessive inflammation in
the oxazolone model of atopic dermatitis. In summary, our results
indicate that in WT mice Pglyrp3 and Pglyrp4 promote efficient
population of the skin with Treg cells in the experimental model of
atopic dermatitis.
Discussion
Skin diseases such as atopic dermatitis and contact dermatitis
involve complex interactions of many cell types. Atopic dermatitis
is thought to have Th2 bias [2,26], but recent findings also show
involvement of Th17 cells [32,33]. The initially identified in vivo
role of Th17 cells was promoting some autoimmune diseases and
recruitment of PMNs to the sites of inflammation [34–37].
However, Th17 cells have many other functions – they play a role
in inflammatory bowel diseases, skin diseases, asthma, graft
rejection, atherosclerosis, periodontal disease, and arthritis
[32,33,38–40]. We extend these findings by showing that Th17
cells exacerbate skin inflammation in experimental model of atopic
dermatitis in a PGRP-dependent manner.
We demonstrate here that Pglyrp3
2/2 and Pglyrp4
2/2 mice
develop more severe oxazolone-induced atopic dermatitis than
WT mice. By contrast, Pglyrp1
2/2 mice develop less severe
oxazolone-induced atopic dermatitis and also less severe contact
dermatitis than WT mice. Thus, individual PGRPs play distinct
roles in these two models of skin diseases: in WT mice Pglyrp3 and
Pglyrp4 protect mice from the development of experimental atopic
dermatitis, whereas Pglyrp1 enhances the development of both
atopic and contact dermatitis and Pglyrp2 has less effect on both
disease models.
The common mechanism underlying these protective effects of
PGRPs is decreased recruitment and activity of Treg cells and
enhanced production and activation of Th17 cells in the affected
skin in Pglyrp3
2/2 and Pglyrp4
2/2 mice, which results in more
severe inflammation and keratinocyte proliferation. Thus, in WT
Figure 9. IL-17 is required for enhanced response to oxazolone
in Pglyrp3
2/2 mice. (A) The level of IL-17-induced chemokine, CXCL-1,
is higher in the ears of Pglyrp3
2/2 mice than WT mice after sensitization
and application of oxazolone for 20 days. (B) Ear swelling in Pglyrp3
2/2
mice sensitized and treated 7 times with oxazolone every other day and
also treated with neutralizing anti-IL-17 mAbs is lower than in Pglyrp3
2/2
mice similarly treated with oxazolone and isotype control IgG. Means 6
SEM; N=6 mice/group; significance of differences between Pglyrp3
2/2
and WT mice (A) or IgG control and anti-IL-17 mAbs-treated mice (B):
*, P,0.05; **, P,0.005.
doi:10.1371/journal.pone.0024961.g009
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Treg cells in the inflamed skin, which limits over-activation of
Th17 cells and protects the skin from exaggerated inflammatory
response to allergens.
Our results do show prominent activation of Th2 cells in the
oxazolone model of atopic dermatitis and prominent production
of IgE, characteristic of Th2 bias in atopic diseases. In our model,
however, the main difference at the peak of inflammation
between WT and atopic dermatitis-sensitive Pglyrp-deficient mice,
which determines the enhanced inflammatory responses and
higher IgE production in Pglyrp-deficient mice, is the over-
activation of Th17 cells and reduced numbers of Treg cells in the
atopic dermatitis-sensitive mice. Our results indicate that initial
Th2 response changes with time to Th17 response and that Th17
cells play an important role in enhancing inflammation and
production of IgE in atopic dermatitis. Our results thus further
extend recent findings of the enhancing role of Th17 cells in
B cell maturation and differentiation [41–43]. Therefore, our
results indicate that Pglyrp3 and Pglyrp4 are involved in
controlling multiple functions of Treg and Th17 cells in the skin
in atopic dermatitis.
Contact dermatitis, which is a skin model of type IV
hypersensitivity, is usually considered to be mediated by Th1
cells. However, this is an oversimplification, because recent
findings show involvement of multiple cell types [2,4,5,44]. Our
results show that Pglyrp1 (and other Pglyrps to a lesser extent)
promotes Th1 responses, because Pglyrp1
2/2 mice (and also
Pglyrp2
2/2 and Pglyrp4
2/2 mice) have reduced inflammation in
oxazolone-induced contact dermatitis. This shift of balance to Th1
cells is likely beneficial for the desirable anti-microbial responses
and may taper exaggerated inflammatory responses in the skin to
allergens. Note that Pglyrp1 is mainly delivered to the sites of
inflammation by PMNs, which are usually recruited to fight
infections.
Our results show that PGRPs, a family of innate immunity
proteins, influence the functions of both innate and adaptive
immune cells with an outcome of enhancing the activity of Treg
cells and inhibiting the activity of Th17 cells. Pglyrp3
2/2 and
Figure 10. Induction of Treg cells by vitamin D reduces the inflammatory response to oxazolone and decreases the numbers of
Th17 cells in the skin of Pglyrp3
2/2 mice. (A) Vitamin D applied to the skin of Pglyrp3
2/2 mice together with oxazolone reduces ear swelling
compared to Pglyrp3
2/2 mice similarly treated with oxazolone alone. (B–D) Vitamin D applied to the skin of Pglyrp3
2/2 mice together with oxazolone
increases the percentages of Treg cells in the ears and cervical lymph nodes and reduces the percentages of Th17 cells in the ears compared to the
application of oxazolone alone, measured on day 20 by flow cytometry. Means 6 SEM of 8 mice/group (A–C; *, P,0.05; **, P,0.005; oxazolone versus
oxazolone + vitamin D) or representative dot plots (D) are shown.
doi:10.1371/journal.pone.0024961.g010
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2/2 mice have decreased numbers of Treg cells and
increased numbers of Th17 cells in the inflamed skin, compared to
WT mice. Allergens and proinflammatory stimuli (such as
oxazolone) in WT mice initially induce vigorous cytokine and
chemokine production. However, upon chronic exposure, WT
mice recruit and maintain large numbers of Treg cells in the
inflamed skin and are able to limit the proinflammatory response
by reducing the number of proinflammatory genes that are
activated and reducing the level of their activation. By contrast,
Pglyrp3
2/2 and Pglyrp4
2/2 mice have fewer Treg cells and higher
numbers of Th17 cells in the affected skin and are unable to limit
inflammatory responses. This T cell imbalance in Treg/Th17 cells
in Pglyrp3
2/2 and Pglyrp4
2/2 mice could come from reduced
recruitment of Treg cells and increased recruitment of Th17 cells
to the affected skin, and/or from enhanced local differentiation of
T cells into Th17 cells (including conversion of Treg cells into
Th17 cells) under the influence of locally produced chemokines
and cytokines. T cell populations are dynamic and have
considerable plasticity based on local cytokine milieu, as, for
example, Treg cells can differentiate into Th17 under the
influence of locally-produced proinflammatory cytokines [45,46].
The enhanced recruitment and differentiation of Th17 cells is
supported by higher production of Th17 cell promoting cytokines
(IL-17, IL-22, IL-23) in the inflamed skin in Pglyrp3
2/2 and
Pglyrp4
2/2 mice. Decreased recruitment of Treg cells to the
inflamed skin is supported by the presence of adequate numbers of
Treg cells and adequate expression of receptors for Treg-attracting
chemokines on these Treg cells in the draining lymph nodes and
spleen in oxazolone-treated Pglyrp3
2/2 mice, but lower numbers
in the skin than in WT mice. These results suggest efficient
generation of induced Treg cells in lymphoid organs but defective
recruitment to the inflamed skin. This mechanism is further
supported by decreased production of Treg cell-attracting
chemokines (CCL1, CCL17, CCL27) in the skin of Pglyrp3
2/2
and Pglyrp4
2/2 mice. Thus both increased recruitment and
generation of Th17 cells and decreased recruitment and retention
of Treg cells in the skin are likely responsible for increased
inflammation in Pglyrp3
2/2 and Pglyrp4
2/2 mice.
Pglyrp3 and Pglyrp4 are primarily expressed in keratinocytes
and other epithelial cells, but not in immune cells and stimulation
of immune cells does not induce expression of Pglyrp3 and Pglyrp4
[7,8,18,20,21]. Our results extend these findings by showing
expression of Pglyrp3 and Pglyrp4 in differentiated keratinocytes
in untreated and oxazolone-treated skin, and no expression of
Pglyrp3 and Pglyrp4 in the inflammatory cells infiltrating the skin
and in the draining lymph nodes, which primarily contain resting
and activated lymphocytes and antigen-presenting cells that
migrated from the inflamed skin. Thus, Pglyrp3 and Pglyrp4
most likely exert their anti-inflammatory effect in the skin through
their expression in keratinocytes. Keratinocytes are an important
local source of chemokines and cytokines, and activation of
keratinocytes by proinflammatory stimuli also leads to increased
expression of Pglyrp3 and Pglyrp4 in the skin, which correlates
with the ability of WT mice to reduce chronic inflammation in the
skin. By contrast, increased Pglyrp1 expression in the inflamed skin
likely comes from the influx of PMNs, because PMNs express high
amounts of Pglyrp1 in their granules and, unlike other PGRPs,
Pglyrp1 expression is not increased by proinflammatory stimuli in
epithelial cells, including keratinocytes [7,8,14,15]. Thus, the
effects of PGRPs in the inflamed skin are likely exerted through a
change in the local production of chemokines and cytokines in the
skin, which modulates the recruitment and activity of these Treg
and Th17 cells. In Pglyrp3
2/2 and Pglyrp4
2/2 mice reduced
numbers of Treg cells allow dominating expansion of Th17 cells,
which can increase inflammatory responses in the atopic
dermatitis model, but may reduce Th1-mediated response in the
contact dermatitis model by shifting T cell differentiation into
Th17 cells instead of Th1 cells. Thus in WT mice, compared to
Pglyrp3
2/2 and Pglyrp4
2/2 mice, the immune balance is shifted
towards Th1 cells, which are protective against microbial
infections (rather than Th17 cells) and towards Treg cells that
control detrimental inflammation induced by proinflammatory
chemicals and allergens. Our results suggest that defects in Pglyrp3
and Pglyrp4 genes could be predisposing to atopic dermatitis
through the aforementioned shifts in immune homeostasis.
Materials and Methods
Ethics statement
All experiments on mice were performed according to the
guidelines and approved by the Indiana University School of
Medicine–Northwest Institutional Animal Care and Use Com-
mittee (approval number IUSM-NW-16).
Mice
We generated Pglyrp1
2/2, Pglyrp2
2/2, Pglyrp3
2/2, and
Pglyrp4
2/2 mice as described previously [15,22,25]. We generated
Pglyrp1
2/2Pglyrp2
2/2, Pglyrp1
2/2Pglyrp3
2/2, and Pglyrp2
2/2
Pglyrp3
2/2 double knockout mice and Pglyrp1
2/2Pglyrp2
2/2
Pglyrp3
2/2 and Pglyrp1
2/2Pglyrp2
2/2Pglyrp4
2/2 triple knockout
mice by breeding single and double knockout mice (all on BALB/c
background) and screening for homozygous deletion of each Pglyrp
gene by PCR analysis of genomic DNA as previously described
[15,22,25]. The lack of expression of the Pglyrp genes was
confirmed by qRT-PCR in mRNA from the ears. Double and
triple homozygous Pglyrp knockout mice were viable and fertile,
bred normally, and yielded the expected male:female ratios and
similar litter size as the wild type and heterozygous mice. They had
similar weight as the WT and single Pglyrp knockout mice and
developed normally with no obvious defects. Their major internal
organs had normal macroscopic appearance, and normal
histological appearance on hematoxylin/eosin-stained sections.
All mice used in experiments were 8–10 week-old and on
BALB/c background. The original colony founder WT BALB/c
breeder mice were obtained from Harlan-Sprague-Dawley. All
knockout mice were backcrossed to the same WT BALB/c mice
from our breeding colony, and all WT and knockout mice were
bred and kept under conventional pathogen-free conditions in the
same room in our facility to minimize the influence of differences
in the environment. For each experiment, mice from several
different cages and breeder pairs were used. The BALB/c
background of Pglyrp-deficient mice and their negative status for
all common viral and bacterial pathogens and parasites were
confirmed as previously described [22].
Oxazolone atopic dermatitis and contact dermatitis
models
To induce atopic dermatitis female mice were first sensitized
with 10 ml of 5% oxazolone (in 80% acetone, 20% olive oil)
applied to the abdomen (after removing hair with Nair cream); 6
days later applications of 30 ml of 0.1% oxazolone (in 80%
acetone, 20% olive oil) to each ear (15 ml to each side) were started
(day 0) and continued every other day through day 18 [26]. In
some experiments to induce Treg cells [30,31] 3 mM vitamin D
(1a,25-dihydroxyvitamin D3 from Sigma) was added to the
oxazolone solution and used for the initial sensitization and
applications to the ears. Ear thickness was measured each time
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toyo, Japan) under constant pressure at the lowest setting. Ear
swelling was determined by subtracting the untreated ear
thickness. The significance of differences in ear swelling was
determined using t-test.
To induce contact dermatitis female mice were first sensitized
with 50 ml of 2% oxazolone (Sigma, in 80% acetone, 20% olive oil)
applied to the abdomen (after removing hair with Nair cream) and
5 ml applied to each paw. The contact dermatitis reaction was then
elicited 6 days later with a single application of 20 mlo f1 %
oxazolone (in 80% acetone, 20% olive oil) to each ear (10 mlt o
each side) [27,28]. Ear thickness was measured as described above
before and 24 and 48 hrs after oxazolone application, and ear
swelling was determined by subtracting the untreated ear
thickness. The significance of differences in ear swelling was
determined using t-test.
Histology and immunohistochemistry
For histological analysis ears were fixed in Bouin’s fixative,
postfixed in 70% ethanol, and embedded in paraffin, and 5 mm
cross-sections were stained with hematoxylin/eosin, and eval-
uated microscopically. For immunohistochemistry, antibodies to
mouse Pglyrp3 and Pglyrp4 were obtained by immunizing rabbits
with peptides corresponding to the following amino acids:
CLVPQHSEIPKKA for Pglyrp3 (exon 5), and CWENPQTDQV-
SEG for Pglyrp4 (exon 2), coupled to KLH, followed by affinity
purification on SulfoLink gel (Pierce) with corresponding peptides
linked through the N-terminal Cys, elution with Tris-glycine
buffer, pH 2.5, and dialysis against PBS, pH 7.2. A rabbit IgG
antibody to a different peptide, which did not react with mouse
Pglyrp3 and Pglyrp4, prepared and purified by the same method,
was used as a negative control. Paraffin 5 mm cross-sections of
were stained by the immunoperoxidase method as previously
described [8], including standard deparaffinization, re-hydration,
quenching of endogenous peroxidase by 30 min incubation in
0.3% H2O2, and incubation with 0.5 mg/ml of anti-Pglyrp3 or
Pglyrp4 antibodies or control IgG overnight, followed by
biotinylated second Ab and Vectastain Elite ABC kit (Vector)
with DAB as a substrate (which generates brown reaction product)
and counterstaining with hematoxylin (blue).
RNA and quantitative real-time reverse transcription PCR
(qRT-PCR)
RNA was isolated from either the entire untreated or treated
ears or lymph nodes using the TRIZOL method (InVitrogen),
followed by digestion with RNase-free DNase (Qiagen) and
purification on RNeasy spin columns using RNeasy Minikit
(Qiagen). Quantitative reverse transcription real-time PCR (qRT-
PCR) was used to quantify the amounts of mRNA in the ears or
lymph nodes using custom RT
2 Profiler PCR Arrays designed by
us and manufactured by Qiagen/SA Biosciences, as previously
described [22,25]. The arrays typically included 30 to 44 assay
genes, 5 housekeeping genes and reverse transcription efficiency
and DNA contamination controls. All primer sets were from
Qiagen/SA Biosciences, except the following primers designed by
us: Pglyrp1, exons 1 and 2 primers, GTGGTGATCTCACACA-
CAGC and GTGTGGTCACCCTTGATGTT; Pglyrp2, exons 3
and 4 primers, ACCAGGATGTGCGCAAGTGGGAT and
AGTGACCCAGTGTAGTTGCCCA; and Pglyrp4, exons 4
and 5 primers, CGACCAGGGCTACAAGAA and CCAGG-
CAGTCTTCACTTTTC. cDNA was synthesized from 2 mgo f
RNA using RT
2 PCR Array First Strand Kit (Qiagen/SA
Biosciences) and the arrays were performed according to the
manufacturer instructions using Qiagen/SA Biosciences Master
Mix. The lists of genes are provided in the figures. The
experiments were performed on RNA pooled from 4–5 mice/
group and repeated 3 times usually with another set of 4–5 mice/
group (usually total of 8–10 mice per treatment).
For each gene, DCt was calculated using the same threshold
(0.2) for all genes and Ct#35 considered as no expression,
followed by normalization to 5 housekeeping genes (Hsp90ab1,
Gusb, Hprt1, Gapdh, and Actb) included in each array, followed
by calculation of DDCt for each gene from two arrays: DDCt =
DCt12DCt2, where DCt1 is the oxazolone treated mice and
DCT2 is the untreated mice, using the program provided by
Qiagen/SA Biosciences. This calculation gives the fold increase in
expression of each gene in the treated mice versus untreated mice
per mg RNA. The genomic DNA contamination controls, reverse
transcription controls, and positive PCR controls were included in
each array and were all passed. Additional control to assure
amplification from RNA, but not from possible contaminating
DNA included parallel reaction sets from which reverse transcrip-
tase was omitted, and which showed no amplification. To compare
baseline gene expression in untreated mice, DCT1 was from
untreated PGRP-deficient mice and DCT2 was from untreated
WT mice.
The results were reported as mean fold increases after
oxazolone treatment (treated/untreated) for WT mice, or ratios
of fold increases in Pglyrp-deficient to WT mice, calculated as
follows: [(Pglyrp
2/2 treated)/(Pglyrp
2/2 untreated)]/[(WT treat-
ed)/(WT untreated)] and presented as heat maps or bar graphs.
The latter fold differences (ratios) of .1o r,1 reflect higher or
lower expression levels of the genes (respectively) in Pglyrp-deficient
than in WT mice. Heat maps were generated using Java TreeView
after converting ,1 ratios to negative fold difference using the
formula: (21)/ratio. In some bar graph figures, ,1 ratios were
also converted to negative fold difference using the formula: (21)/
ratio. The significance of differences in gene activation between
groups of mice was determined using the two-sample one-tailed t-
test, and typically the differences of .2 fold were significant at
P,0.05.
Expression of mRNA for PGRPs and some chemokine
receptors was similarly measured by qRT-PCR using Qiagen/
SA Biosciences First Strand Kit (with random primers) and
amplification for 40 cycles with Qiagen/SA Biosciences SYBR
Green Master Mix, and calculated using comparative cycle
threshold method with 5 housekeeping genes (Hsp90ab1, Gusb,
Hprt1, Gapdh, and Actb) as controls.
Isolation of cells and flow cytometry
Mouse ears were placed in RPMI-1640 with 3 mg/ml of
Dispase II (Roche), separated into dorsal and ventral halves and
scored on the dermal side with a scalpel. The tissue was digested
for 8 hrs at 37uCi n5 %C O 2. Dermis was then separated from the
epidermis and epidermis was further digested with 0.25% trypsin
in RPMI-1640 for 10 min at 37uC. Cells were washed twice with
RPMI-1640 with 5% fetal bovine serum (FBS) and incubated for
20 hrs in the same medium at 37uCi n5 %C O 2. Cells were then
strained through a 40 mm filter and resuspended at 2.0610
7 cells/
ml in RPMI-1640 with 5% FBS. Single cells from cervical lymph
nodes and spleen were obtained by passing the tissue through a
40 mm filter, red blood cells were removed from the spleen cells
with a lysis buffer (Biolegend), and cells were suspended at
2.0610
7 cells/ml in RPMI-1640 with 5% FBS.
1610
6 cells were stained with CD4-APC (clone RM4-5,
Biolegend) antibody for 20 min at 4uC. CD4-stained cells were
then stained for Foxp3-PE (clone FJK-16s, eBioscience) or for
cytokines IFN-c-PE (clone XMG1.2), IL4-PE (clone 11B11) and
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used at 0.2 mg/1610
6 cells according to Biolegend protocols using
Biolegend buffers. Prior to staining for cytokines, CD4-APC
stained cells were activated with TPA (12-O-Tetradecanoylphor-
bol 13-acetate, 25 ng/ml) and ionomycin (250 ng/ml) in the
presence of the Golgi inhibitor, monensin, for 4 hrs at 37uCi n5 %
CO2. Cells were analyzed by flow cytometry using MACSQuant
(Miltenyi) cytometer. Foxp3, IFN-c, IL-4 and IL-17 positive cells
were measured within the CD4
+ gate.
Neutralization of IL-17 and ELISA
IL-17 was neutralized by intravenous injections of anti-IL-17
mAb (specific for IL-17A and not reactive with IL-1F, rat clone
50104, endotoxin-free from R&D Systems) 100 mg at sensitization
and 50 mg on days 0, 3, 6, 9, 12, and 15 of oxazolone treatment.
Control mice were similarly treated with isotype control rat
IgG2ak mAb (clone 16-4321, endotoxin-free from eBioscience).
The amount of CXCL-1 in ears was measured by ELISA as
previously described [25], after each ear was homogenized with
Polytron in 0.5 ml of PBS (without Ca/Mg) with 1 mM EDTA,
1 mM PMSF, 1:100 dilution of protease inhibitors (Sigma P1860),
and 0.5% Triton X-100, followed by sonication and centrifuga-
tion.
Supporting Information
Figure S1 Pglyrp3
2/2 and Pglyrp4
2/2 mice have in-
creased Th17 cells in the affected skin in the oxazolone
atopic dermatitis model. Expression of a panel of marker
genes characteristic of various inflammatory cell types in the ears
of mice after sensitization and 10 applications of oxazolone to the
ears every other day measured by qRT-PCR (day 20) is shown.
For WT mice (top panel), the ratio of the amount of mRNA in
oxazolone-treated to untreated mice for each gene (fold induction
by oxazolone) is shown; for Pglyrp
2/2 mice, the results are the
ratios of fold induction of each gene by oxazolone in Pglyrp
2/2
mice to fold induction of each gene by oxazolone in WT mice
(which represents the fold difference in the response to oxazolone
in Pglyrp
2/2 versus WT mice). The results are means 6 SEM of 3
arrays from 4–5 mice/group and are shown as heat maps in
Figure 6A in the main article.
(PDF)
Figure S2 In the oxazolone contact dermatitis model in
Pglyrp1
2/2 and Pglyrp2
2/2 mice most cell types are
decreased in the affected skin, but Treg cells and B cells
are increased. Expression of a panel of marker genes
characteristic of various inflammatory cell types in the ears of
mice after sensitization and 6 hrs after single application of
oxazolone to the ears measured by qRT-PCR is shown. For WT
mice (top panel), the ratio of the amount of mRNA in oxazolone-
treated to untreated mice for each gene (fold induction by
oxazolone) is shown; for Pglyrp
2/2 mice, the results are the ratios
of fold induction of each gene by oxazolone in Pglyrp
2/2 mice to
fold induction of each gene by oxazolone in WT mice (which
represents the fold difference in the response to oxazolone in
Pglyrp
2/2 versus WT mice). The results are means 6 SEM of 3
arrays from 4–5 mice/group and are shown as heat maps in
Figure 6B in the main article.
(PDF)
Figure S3 Multiple inflammatory and immune genes
are induced at an early stage of oxazolone model of
atopic dermatitis. Expression of a panel of cytokines,
chemokines, and other marker genes characteristic of Th1, Th2,
Th17, Treg, NK, and other cell types in the ears of mice after
sensitization and 7 applications of oxazolone to the ears every
other day measured by qRT-PCR (day 13). For WT mice (top
panel), the ratio of the amount of mRNA in oxazolone-treated to
untreated mice for each gene (fold induction by oxazolone) is
shown; for Pglyrp3
2/2 or Pglyrp4
2/2 mice, the results are the ratios
of fold induction of each gene by oxazolone in Pglyrp
2/2 mice to
fold induction of each gene by oxazolone in WT mice (which
represents the fold difference in the response to oxazolone in
Pglyrp
2/2 versus WT mice). The results are means 6 SEM of 3
arrays from 4–5 mice/group and are shown as heat maps in
Figure 7A in the main article.
(PDF)
Figure S4 Th17 gene expression profile is preferentially
induced in the oxazolone model of atopic dermatitis in
Pglyrp3
2/2 and Pglyrp4
2/2 mice. Expression of a panel of
cytokines, chemokines, and other marker genes characteristic of
Th1, Th2, Th17, Treg, NK, and other cell types in the ears of
mice after sensitization and 10 applications of oxazolone to the
ears every other day shows higher induction of several Th17
marker genes in Pglyrp3
2/2 and Pglyrp4
2/2 compared to WT mice
measured by qRT-PCR. For WT mice (top panel), the ratio of the
amount of mRNA in oxazolone-treated to untreated mice for each
gene (fold induction by oxazolone) is shown; for Pglyrp
2/2 mice,
the results are the ratios of fold induction of each gene by
oxazolone in Pglyrp
2/2 mice to fold induction of each gene by
oxazolone in WT mice (which represents the fold difference in the
response to oxazolone in Pglyrp
2/2 versus WT mice). The results
are means 6 SEM of 3–4 arrays from 4–5 mice/group and are
shown as heat maps in Figure 7A in the main article.
(PDF)
Figure S5 Expression of most immune genes is reduced
in the oxazolone model of contact dermatitis in Pglyrp
2/2
mice. Expression of a panel of cytokines, chemokines, and other
marker genes characteristic of Th1, Th2, Th17, Treg, NK, and
other cell types in the ears of mice after sensitization and a single
application of oxazolone to the ears shows lower induction of
immune marker genes in Pglyrp
2/2 mice compared to WT mice
measured by qRT-PCR. For WT mice (top panel), the ratio of the
amount of mRNA in oxazolone-treated to untreated mice for each
gene (fold induction by oxazolone) is shown; for Pglyrp
2/2 mice,
the results are the ratios of fold induction of each gene by
oxazolone in Pglyrp
2/2 mice to fold induction of each gene by
oxazolone in WT mice (which represents the fold difference in the
response to oxazolone in Pglyrp
2/2 versus WT mice, negative
numbers show lower gene induction in Pglyrp
2/2 than in WT
mice). The results are means 6 SEM of 3–4 arrays from 4–5
mice/group and are shown as heat maps in Figure 7B in the main
article.
(PDF)
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